Ricardo Invests in a Hydrogen Development and Testing Facility Leading the Way in the Future of Sustainable Transport
28.1.2021 03:01:00 EET | Business Wire | Press release
As part of its mission to support the decarbonisation of the global transport and energy sectors, Ricardo, a world-class environmental, engineering and strategic consulting company, has today announced an initial investment of £2.5million to build a hydrogen development and test facility at its Shoreham Technical Centre in the UK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210127006018/en/
Hydrogen-fuel cell (Photo: Business Wire)
Designed to support the company’s existing work in hydrogen, fuel cells and green alternative fuels, the new facility will deliver state-of-the-art test and development to advance capability in both alternative fuels and electric vehicles. It will significantly increase the range of hydrogen and fuel cell services and solutions which can be delivered to Ricardo’s global customers.
Steve Dyke, Managing Director of Ricardo Automotive and Industrial said: “We are already working with a range of clients on hydrogen and fuel cell technology, providing clean efficient solutions which reduce carbon and noxious emissions across a wide range of sectors. By building our hydrogen fuel cell and propulsion capability, we shall further advance our facilities and technology for clean vehicles across all transport sectors, and increase the range of hydrogen and fuel cell services and solutions that we can offer to our clients.
“A particular focus for the new facility will be a systems-led approach to vehicle development, integrating our enhanced test capability with our leading-edge digital and simulation tools to deliver fully optimised hardware and software system solutions for our customers. This will further enhance our established digital engineering expertise, allowing the company to provide solutions which: are greener because they are less energy and resource-intensive; remove risk from development through more efficient, faster digital techniques; and reduce cost and time to market to provide competitive advantage.”
This investment is a further boost to Ricardo’s hydrogen capability, following the company’s announcement on 14 January 2021 of a collaboration with AFC Energy plc aimed at identifying new and innovative alternative fuel solutions, including hydrogen power applications.
Fuel cell test facilities with this level of capability to develop and test hydrogen technologies are rare across the globe, so this investment will accelerate Ricardo’s position as a leader in hydrogen transport technology.
Ends
About Ricardo
Ricardo plc is a world-class environmental, engineering and strategic consulting company listed on the London Stock Exchange. With over 100 years of engineering excellence, we provide exceptional levels of expertise in delivering leading edge and innovative cross sector sustainable products and solutions, helping our global customers increase efficiencies, achieve growth and create a clear and safer future. Our mission is clear -- to create a world fit for the future. For more information visit www.ricardo.com
About Ricardo Automotive and Industrial Division
Ricardo Automotive & Industrial Ricardo Automotive and Industrial, a division of Ricardo plc, provides global engineering services for OEMs across all transport sectors. The vision is to be the consulting partner of choice for clean efficient, integrated propulsion and energy solutions, underpinned by digitisation.
Ricardo is a supporter of the UK Hydrogen Strategy Now campaign. This group of leading UK businesses which has together committed to invest £3bn into hydrogen projects is calling on the Chancellor of the Exchequer for a UK-wide hydrogen strategy.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210127006018/en/
Contact information
For Ricardo:
Kathryn Bellamy
Communications Manager
Ricardo Automotive & Industrial, and Performance Products
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
Ricardo Media Office
Gill Gibbons
Email: media@ricardo.com
Telephone: +44 (0) 7795 342804
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 14:00:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat Gaurav and Executive Vice President, EMEA, Fabienne Cêtre, will open the mainstage with an exploration of the market forces reshaping global supply chains and how operational orc
Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 14:00:00 EEST | Press release
Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring and strengthen treatment decisions compared with conventional brain monitoring.” — Rasmus Madsen, CEO, Cebreo Medical Designed to resemble a hearing aid, NeuroBuds is built to minimize the stigma and burden that typically limit complianc
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, alongside cognitive and emotional patterns, including getting stuck in negative or repetitive ways of thinking, difficulty shifting perspective or navigating emotions, and feeling disconnected from pleasure or motivation1-8. While TRD originates as MDD, its burden and resistance to standard treatments distinguish it as a more complex condition. Compared to MDD, TRD patients experience almost 3x long
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 13:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these signals to inform where they plan and prioritize media investment. “Marketers shouldn’t have to guess where demand is coming from before they invest,
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 13:00:00 EEST | Press release
QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom